Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

1.85
+0.02001.09%
Post-market: 1.900.0542+2.93%17:09 EDT
Volume:2.50M
Turnover:4.71M
Market Cap:333.16M
PE:-4.58
High:1.94
Open:1.88
Low:1.84
Close:1.83
52wk High:6.88
52wk Low:1.61
Shares:180.09M
Float Shares:132.00M
Volume Ratio:0.87
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:2.01
PE(LYR):-4.39

Loading ...

Company Profile

Company Name:
Compass Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
39
Office Location:
80 Guest Street,Suite 601,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.